Table 3.
Median survival (months) for patients vaccinated with either the nonemulsive or the emulsive formulation according to the site of metastases.
SITE OF METASTASES | FORMULATION | GLOBAL | |
---|---|---|---|
NON EMULSIVE-SC | EMULSIVE-IM | ||
Non visceral n = 45 | 31,633 (n = 24) | 16,533 (n = 21) | 22,533 |
Visceral n = 48 | 21,033 (n = 24) | 6,267 (n = 24) | 8,800 |
Non visceral (log rank P = 0.118)/HR (95% CI): 0.535 (0.241–1.186) Visceral (log rank P = 0.005)/HR (95% CI): 0.375 (0.184–0.766) |